MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
1.201
-0.059
-4.67%
Opening 11:19 05/29 EDT
OPEN
1.280
PREV CLOSE
1.260
HIGH
1.280
LOW
1.185
VOLUME
337.22K
TURNOVER
--
52 WEEK HIGH
8.08
52 WEEK LOW
1.010
MARKET CAP
37.09M
P/E (TTM)
-0.2094
1D
5D
1M
3M
1Y
5Y
1D
BioXcel Presents New Data From Phase 3 SERENITY At-Home Trial Evaluating BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia At 2026 ASCP Annual Meeting
Benzinga · 1d ago
BioXcel Therapeutics posts new Phase 3 SERENITY At-Home data for BXCL501 in agitation linked to bipolar disorder, schizophrenia
PUBT · 1d ago
BIOXCEL THERAPEUTICS PRESENTS NEW DATA FROM SERENITY AT-HOME PHASE 3 TRIAL FOR AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA AT 2026 ASCP ANNUAL MEETING
Reuters · 1d ago
Weekly Report: what happened at BTAI last week (0518-0522)?
Weekly Report · 4d ago
Weekly Report: what happened at BTAI last week (0511-0515)?
Weekly Report · 05/18 09:33
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 05/15 12:15
BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)
TipRanks · 05/15 12:03
Earnings Scheduled For May 15, 2026
Benzinga · 05/15 11:11
More
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.